Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-288 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1, Dose 1, ABT-288 | EXPERIMENTAL | Low Dose |
| Arm 2, Dose 2, ABT-288 | EXPERIMENTAL | High dose |
| donepezil | ACTIVE_COMPARATOR | - |
| sugar pill | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | ABT-288 vs placebo capsules administered orally once daily for 14 days |
| 2 | EXPERIMENTAL | ABT-288 vs placebo capsules administered orally once daily for 14 days |
| 3 | EXPERIMENTAL | ABT-288 vs placebo capsules administered orally once daily for 14 days |
| 4 | EXPERIMENTAL | ABT288 vs placebo administered orally once daily for 14 days |
| 5 | EXPERIMENTAL | ABT-288 vs placebo administered orally once daily for 14 days |
| 6 | EXPERIMENTAL | ABT-288 vs placebo administered orally once daily for 14 days |
| 7 | EXPERIMENTAL | ABT-288 vs placebo administered orally once daily for 14 days |
| 8 | EXPERIMENTAL | ABT-288 vs placebo administered orally once daily for 14 days |
| 9 | EXPERIMENTAL | ABT-288 vs placebo administered orally once daily for 14 days |
| Name | Type | Description |
|---|---|---|
| ABT-288 | DRUG | Subjects will take 4 capsules once daily for 12 weeks. |
| donepezil | DRUG | Subjects will take 4 capsules once daily for 12 weeks. |
| placebo | DRUG | Subjects will take 4 capsules once daily for 12 weeks. |
Inclusion Criteria: 1. Have voluntarily signed an informed consent. 2. Subject meets diagnostic criteria criteria for probable AD (Alzheimer's Disease). 3. Female subjects must be postmenopausal for at least 2 years or surgically sterile. 4. Male subjects must be surgically sterile, sexually inactiv...
Top 20 of 24 competitors
ABT-288 is an investigational small molecule being developed by AbbVie Inc. for the treatment of schizophrenia and Alzheimer's disease. It has been studied in clinical trials for these neurological conditions, including a Phase 2 study in patients with mild-to-moderate Alzheimer's disease.
ABT-288 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. AbbVie has conducted clinical trials of ABT-288 in schizophrenia and Alzheimer's disease.
ABT-288 is an investigational drug that has completed Phase 2 clinical development. It is not FDA approved and remains in clinical development. The most advanced study was a Phase 2 trial in Alzheimer's disease, which has been completed.
ABT-288 has been studied in two completed clinical trials. NCT00888693 was a Phase 1 multiple dose study in stable subjects with schizophrenia. NCT01018875 was a Phase 2 efficacy and safety study in subjects with mild-to-moderate Alzheimer's disease, conducted in Russia and Ukraine.
ABT-288 is the investigational code name for this compound developed by AbbVie. No alternative brand names or other designations have been associated with this drug in the available clinical trial information.